Table 1:
Baseline characteristics of ARTEMIS trial participants
| All (n=110) | ARTEMIS (n=55) | Attention-Control (n=55) | p-value | |
|---|---|---|---|---|
|
| ||||
| M (SD) | M (SD) | M (SD) | ||
|
| ||||
| Age | 43.2 (8.9) | 43.2 (9.2) | 43.2 (8.5) | 0.88 |
| Time since HIV diagnosis (Years) | 12.9 (8.6) | 13.4 (8.9) | 12.5 (8/4) | 0.62 |
| CD4+ T-cell count (cells/mm3) | 620.9 (298.1) | 642.9 (272.8) | 639.9 (313.6) | 0.99 |
|
| ||||
| n (%) | n (%) | n (%) | ||
|
| ||||
| Race/Ethnicity | 0.12 | |||
| Black/African American | 18 (16.4) | 9 (8.2) | 9 (8.2) | |
| White | 47 (42.7) | 18 (32.7) | 29 (52.7) | |
| Hispanic/Latino | 32 (29.1) | 21 (38.2) | 11 (20.0) | |
| Other ethnic minority | 13 (11.8) | 7 (12.7) | 6 (10.9) | |
|
| ||||
| Education | 0.62 | |||
| Less than high school | 8 (7.3) | 5 (9.1) | 3 (5.5) | |
| HS graduate | 17 (15.5) | 8 (14.6) | 9 (16.4) | |
| Some college/trade school | 57 (51.8) | 25 (45.5) | 32 (58.2) | |
| College graduate | 17 (15.5) | 10 (18.2) | 7 (12.7) | |
| Post graduate | 11 (10.0) | 7 (12.7) | 4 (7.3) | |
|
| ||||
| Income | 0.26 | |||
| < $4,999 | 16 (14.5) | 8 (14.8) | 8 (14.6) | |
| $5,000 – $11,999 | 28 (35.5) | 9 (16.7) | 19 (34.6) | |
| $12,000 – $15,999 | 27 (24.5) | 14 (25.9) | 13 (23.6) | |
| $16,000 – $24,999 | 12 (10.9) | 6 (11.1) | 6 (10.9) | |
| $25,000 – $34,999 | 9 (8.2) | 4 (7.4) | 5 (9.1) | |
| $35,000 – $49,999 | 9 (8.2) | 7 (13.0) | 2 (3.6) | |
| >$50,000 | 8 (7.3) | 6 (11.1) | 2 (3.6) | |
|
| ||||
| HIV viral load ≥ 200 copies/mL | 15 (13.6) | 6 (11.1) | 9 (16.7) | 0/14 |
ARTEMIS = affect regulation to enhance methamphetamine intervention success